Two drugs used together slowed a brain tumor in mice
Original title: Combination of ALK2 and cholesterol targeting agents exploits linked genetic and metabolic dependencies in diffuse midline glioma
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was only done in lab cells and in mice.
The short version
A common cholesterol pill helped a targeted drug work better in mice with a hard brain tumor.
What was studied. Researchers looked at diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary, a brain tumor driven by changes in how genes are switched on and off. About 25% of these patients have a change in a gene called ACVR1. That gene makes a protein called ALK2. The team tested drugs that block ALK2, alone and with statins, the pills people take for cholesterol.
What they found. Drugs that block ALK2 did not do much on their own in animals. Lab tests showed ALK2 also helps the tumor cells handle cholesterol. Mice given an ALK2 blocker plus a statin lived longer than mice given no drug. When the tumor cells shifted to a different cell type, the drug pair worked less well.
What this means, and what it doesn't
What it could mean: This points to a drug pair that may be worth testing in people. Statins are already in use and are usually easy to tolerate. That could make a future trial simpler to set up.
What it doesn't mean: This is not a cure, and it is not care you can get today. The work was done in lab cells and in mice, not in patients. We do not know yet if it helps people or is safe for them. Do not start or change any medicine on your own. Talk to your care team first.
Source: bioRxiv (preprint), September 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.